Exabis Library
Welcome to the e-CCO Library!
P669: Effect of vedolizumab therapy on whole blood transcriptional profiles in patients with Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P669: Human β-defensin 2 suppresses TNF-α secretion in human and mouse dendritic cells mediated by chemokine receptor-2
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P669: Improving Crohn's disease stricture dilation outcome: Effect of repeated dilation, needle knife stricturotomy, and ongoing active inflammation
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P669: Transmural healing is associated with higher infliximab trough levels in Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P669: Validation of prior infliximab exposure and total colectomy outcome in patients with ulcerative colitis in Sweden
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P670 Usefulness of monitoring the concentration of azathioprine metabolites in the children with inflammatory bowel disease and autoimmune hepatitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P670: Comparative efficacy on steroid-free remission of pharmacological therapies for moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P670: Evaluating the management of Vitamin D in Crohn's disease patients in a secondary care population
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P670: Familial Inflammatory Bowel Disease is associated with a more adverse disease compared to sporadic cases
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P670: Identification of two additional susceptibility loci for Crohn's disease in Koreans
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P670: Therapeutic efficacy and economic impact of half sulfasalazine therapy for refractory ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P670: “What Matters To You?” – How do patient views compare with a patient experience framework and UK national standards of care?
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P671 Natural history and clinical outcomes of patients with ulcerative colitis who are intolerant to 5-aminosalicylic acid agents: A multi-centre cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P671: Calprotectin does not add accuracy to PRO2 for prediction of continuous clinical response in moderate-to-severe ulcerative colitis patients treated with golimumab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P671: Early suppression of the serological macrophage activity biomarker VICM, and not suppression of CRP, predicts the response to infliximab in Crohn's disease patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P671: Effect of genetic polymorphisms in the folate pathway on the efficacy and safety of methotrexate in Crohn’s disease.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P671: Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands: a retrospective observational study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P671: Occurrence and clinical impact of eosinophilic esophagitis in a large cohort of children with Inflammatory Bowel Disease.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P671: Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Results from the UniStar study long-term extension
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:12 AM
P672 The escalation of therapy or intervention (ETI) calculator for ulcerative colitis: does it have the potential to help outpatient capacity meet demand?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM